Revvity Inc
RVTY
Company Profile
Business description
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.
Contact
77 4th Avenue
WalthamMA02451
USAT: +1 781 663-6900
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,121.90 | 13.60 | 0.15% |
| CAC 40 | 8,074.23 | 6.70 | 0.08% |
| DAX 40 | 24,049.74 | 100.63 | 0.42% |
| Dow JONES (US) | 47,311.00 | 225.76 | 0.48% |
| FTSE 100 | 9,777.08 | 62.12 | 0.64% |
| HKSE | 25,935.41 | 16.99 | -0.07% |
| NASDAQ | 23,499.80 | 151.16 | 0.65% |
| Nikkei 225 | 51,168.50 | 956.23 | 1.90% |
| NZX 50 Index | 13,632.65 | 11.67 | 0.09% |
| S&P 500 | 6,796.29 | 24.74 | 0.37% |
| S&P/ASX 200 | 8,852.50 | 15.70 | 0.18% |
| SSE Composite Index | 3,969.25 | 9.06 | 0.23% |